Overall, our study demonstrates that L19-IL2 selectively binds to EDB-FN1 expressed in the TME, promoting immune infiltration and activation within the tumor core and significantly enhancing the anti-tumor effects of second-line chemotherapy. This evidence concerns the gene FN1 and neoplasm.